STOCK TITAN

Theratechnologies to Announce Financial Results for Its Second Quarter Fiscal 2021

MONTREAL, June 30, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (THTX) plans to release its financial results for Q2 fiscal 2021, ending May 31, 2021, on July 15, 2021.

(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags

Rhea-AI Summary

MONTREAL, June 30, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (THTX) plans to release its financial results for Q2 fiscal 2021, ending May 31, 2021, on July 15, 2021. A conference call will be held at 8:30 a.m. ET to discuss these results, hosted by CEO Paul Lévesque. Interested parties can access the call at 1-844-400-1697 or via webcast. A replay will be available the same day and until July 22, 2021. Theratechnologies focuses on innovative therapies addressing unmet medical needs.

Loading...
Loading translation...

Positive

  • Schedule for Q2 fiscal 2021 financial results indicates transparency and investor engagement.

Negative

  • None.
Argus Session date unavailable
+0.78% session move Open Argus
Details

News Market Reaction – THTX

The recorded move for THTX in the trading session of this news was +0.78%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

MONTREAL, June 30, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies announced today that it will report its financial results for the second quarter of fiscal 2021 ended May 31, 2021 on Wednesday, July 15, 2021.

The Company will host a conference call and webcast at 8:30 a.m. (ET) to discuss the results hosted by Paul Lévesque, President and Chief Executive Officer.

The conference call can be accessed by dialing 1-844-400-1697 (toll free) or 1-703-736-7400 (International). The conference call will also be accessible via webcast at https://edge.media-server.com/mmc/p/d9fu3xjc . Phone replay report of the conference call will be available on the same day starting at 11:30 a.m. (ET) until July 22, 2021, by dialing 1-855-859-2056 (North America) or 1-404-537-3406 (International) and by entering the access code: 7943345. The webcast replay is also available until July 15, 2022 on https://edge.media-server.com/mmc/p/d9fu3xjc  

About Theratechnologies
Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Further information about Theratechnologies is available on the Company's website at www.theratech.com, on SEDAR at www.sedar.com and on EDGAR at www.sec.gov.

For media inquiries:
Denis Boucher
Vice President, Communications and Corporate Affairs
514-336-7800

For investor inquiries:
Leah Gibson
Senior Director, Investor Relations
617-356-1009
ir@theratech.com


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Theratechnologies report its financial results for the second quarter of fiscal 2021?

Theratechnologies will report its financial results for the second quarter of fiscal 2021 on July 15, 2021.

What time is the conference call for Theratechnologies' Q2 results?

The conference call for Theratechnologies' Q2 results is scheduled for 8:30 a.m. ET.

How can I access the Theratechnologies Q2 financial results conference call?

You can access the conference call by dialing 1-844-400-1697 (toll free) or via webcast.

What is the focus of Theratechnologies as a biopharmaceutical company?

Theratechnologies focuses on developing and commercializing innovative therapies addressing unmet medical needs.

Keep reading